Evidence map›Paper›PMID 42182501›Full record

ArticlebioRxiv : the preprint server for biology2026

Discovery and Characterization of Interleukin-4-Specific Affibodies for Affinity-Controlled Protein Release and Macrophage Polarization.

Jonathan Dorogin, Astha Lamichhane, Andy J Huang, Justin E Svendsen, Morrhyssey A Benz, Shreya A Raghavan, Marian H Hettiaratchi

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonathan DoroginDepartment of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon.
Astha LamichhaneDepartment of Biomedical Engineering, Texas A&M University.
Andy J HuangDepartment of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon.
Justin E SvendsenDepartment of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon.ORCID 0000-0002-5873-5339
Morrhyssey A BenzDepartment of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon.
Shreya A RaghavanDepartment of Biomedical Engineering, Texas A&M University.ORCID 0000-0002-4631-7762
Marian H HettiaratchiDepartment of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon.ORCID 0000-0001-8187-4575

Funding

Modulating Protein Activity in Tissue Repair using Engineered Affinity-based BiomaterialsR35GM147507 · NIGMS · UNIVERSITY OF OREGON · PI Marian Hirushika Hettiaratchi · 2022 to 2026
$2.0M
Development of affinity-based delivery systems for angiogenic growth factorsF31HL176164 · NHLBI · UNIVERSITY OF OREGON · PI Justin E Svendsen · 2024 to 2026
$147k
NHLBI NIH HHS F31 HL176164NIGMS NIH HHS R35 GM147507
6 · The paper itself

Abstract

Interleukin-4 (IL-4) is a key immunoregulatory cytokine that promotes type 2 inflammation, drives macrophage polarization toward an anti-inflammatory M2 phenotype, and supports tissue repair. However, clinical translation of IL-4 therapies to modulate the immune response is limited by the need for precise control over its delivery to avoid immune dysregulation. Here, we report an affinity-based strategy to modulate IL-4 delivery and bioactivity using engineered affibody proteins. A yeast surface display library was screened via magnetic- and fluorescence-activated cell sorting to identify two IL-4-specific affibodies with moderate binding affinities (dissociation constants, K

Indexed as

affibodyaffinity interactionshydrogelInterleukin-4protein delivery

Identifiers

PMID42182501
PMCPMC13192705

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.